Arca
Skip to content
Tools
Tools

CCR2: C-C chemokine receptor type 2

Key functional receptor for CCL2 but can also bind CCL7, and CCL12.

  • Drugs that act on it: 10
  • Approved: 0
  • In phases 1 to 3: 10
  • Sponsors: 8

Who is on it, and how far along

Every drug ChEMBL records acting on CCR2, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 8
  • Antibody 1
  • Other 1

Approved0

    Phase 31

    • Cenicriviroc

    Phase 29

    • BMS-813160
    • AZD2423
    • BMS-741672
    • Ilacirnon
    • JNJ-41443532
    • MK-0812
    • PF-04634817
    • PF-4136309
    • Plozalizumab

    Phase 10

      Sponsors

      Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 9 of 10 act as: C-C chemokine receptor type 2 antagonist; the rest name their own mechanism.
      CenicrivirocPhase 3Tobira TherapeuticsSmall moleculeAntagonist1
      BMS-813160Phase 2Bristol-Myers SquibbSmall moleculeAntagonist1
      AZD2423Phase 2AstraZeneca PharmaceuticalsOtherAntagonist0
      BMS-741672Phase 2Bristol-Myers SquibbSmall moleculeAntagonist0
      IlacirnonPhase 2AmgenSmall moleculeAntagonist0
      JNJ-41443532Phase 2Johnson & JohnsonSmall moleculeAntagonist0
      MK-0812Phase 2Merck & Co. (MSD)Small moleculeAntagonist0
      PF-04634817Phase 2PfizerSmall moleculeAntagonist0
      PF-4136309Phase 2PfizerSmall moleculeAntagonist0
      PlozalizumabPhase 2Takeda Pharmaceuticals USAAntibodyInhibitorC-C chemokine receptor type 2 inhibitor0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 2 in all, from ClinicalTrials.gov.
      I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill PatientsCenicrivirocPhase 2Active, not recruitingQuantumLeap Healthcare CollaborativeJul 27, 2020
      Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)BMS-813160Phase 2Active, not recruitingIcahn School of Medicine at Mount SinaiOct 10, 2019

      Diseases most associated with it

      Open Targets association score, 0 to 1; all associations

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4015, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P41597, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.